279 related articles for article (PubMed ID: 31502148)
1. Germline Genetics in Immuno-oncology: From Genome-Wide to Targeted Biomarker Strategies.
Kirchhoff T; Ferguson R
Methods Mol Biol; 2020; 2055():93-117. PubMed ID: 31502148
[TBL] [Abstract][Full Text] [Related]
2. Germline genetic host factors as predictive biomarkers in immuno-oncology.
Chat V; Ferguson R; Kirchhoff T
Immunooncol Technol; 2019 Sep; 2():14-21. PubMed ID: 35756849
[TBL] [Abstract][Full Text] [Related]
3. Status of Immune Oncology: Challenges and Opportunities.
Cesano A; Marincola FM; Thurin M
Methods Mol Biol; 2020; 2055():3-21. PubMed ID: 31502145
[TBL] [Abstract][Full Text] [Related]
4. Autoimmune genetic risk variants as germline biomarkers of response to melanoma immune-checkpoint inhibition.
Chat V; Ferguson R; Simpson D; Kazlow E; Lax R; Moran U; Pavlick A; Frederick D; Boland G; Sullivan R; Ribas A; Flaherty K; Osman I; Weber J; Kirchhoff T
Cancer Immunol Immunother; 2019 Jun; 68(6):897-905. PubMed ID: 30863922
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic implications of germline genetic findings in cancer.
Thavaneswaran S; Rath E; Tucker K; Joshua AM; Hess D; Pinese M; Ballinger ML; Thomas DM
Nat Rev Clin Oncol; 2019 Jun; 16(6):386-396. PubMed ID: 30783251
[TBL] [Abstract][Full Text] [Related]
6. Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop.
Bedognetti D; Ceccarelli M; Galluzzi L; Lu R; Palucka K; Samayoa J; Spranger S; Warren S; Wong KK; Ziv E; Chowell D; Coussens LM; De Carvalho DD; DeNardo DG; Galon J; Kaufman HL; Kirchhoff T; Lotze MT; Luke JJ; Minn AJ; Politi K; Shultz LD; Simon R; Thórsson V; Weidhaas JB; Ascierto ML; Ascierto PA; Barnes JM; Barsan V; Bommareddy PK; Bot A; Church SE; Ciliberto G; De Maria A; Draganov D; Ho WS; McGee HM; Monette A; Murphy JF; Nisticò P; Park W; Patel M; Quigley M; Radvanyi L; Raftopoulos H; Rudqvist NP; Snyder A; Sweis RF; Valpione S; Zappasodi R; Butterfield LH; Disis ML; Fox BA; Cesano A; Marincola FM;
J Immunother Cancer; 2019 May; 7(1):131. PubMed ID: 31113486
[TBL] [Abstract][Full Text] [Related]
7. Evolving landscape of tumor molecular profiling for personalized cancer therapy: a comprehensive review.
Syn NL; Yong WP; Goh BC; Lee SC
Expert Opin Drug Metab Toxicol; 2016 Aug; 12(8):911-22. PubMed ID: 27249175
[TBL] [Abstract][Full Text] [Related]
8. Germline Variants That Affect Tumor Progression.
Chatrath A; Ratan A; Dutta A
Trends Genet; 2021 May; 37(5):433-443. PubMed ID: 33203571
[TBL] [Abstract][Full Text] [Related]
9. Targeted next-generation sequencing of pediatric neuro-oncology patients improves diagnosis, identifies pathogenic germline mutations, and directs targeted therapy.
Kline CN; Joseph NM; Grenert JP; van Ziffle J; Talevich E; Onodera C; Aboian M; Cha S; Raleigh DR; Braunstein S; Torkildson J; Samuel D; Bloomer M; Campomanes AGA; Banerjee A; Butowski N; Raffel C; Tihan T; Bollen AW; Phillips JJ; Korn WM; Yeh I; Bastian BC; Gupta N; Mueller S; Perry A; Nicolaides T; Solomon DA
Neuro Oncol; 2017 May; 19(5):699-709. PubMed ID: 28453743
[TBL] [Abstract][Full Text] [Related]
10. Next generation sequencing in cancer: opportunities and challenges for precision cancer medicine.
Paolillo C; Londin E; Fortina P
Scand J Clin Lab Invest Suppl; 2016; 245():S84-91. PubMed ID: 27542004
[TBL] [Abstract][Full Text] [Related]
11. Precancer Atlas to Drive Precision Prevention Trials.
Spira A; Yurgelun MB; Alexandrov L; Rao A; Bejar R; Polyak K; Giannakis M; Shilatifard A; Finn OJ; Dhodapkar M; Kay NE; Braggio E; Vilar E; Mazzilli SA; Rebbeck TR; Garber JE; Velculescu VE; Disis ML; Wallace DC; Lippman SM
Cancer Res; 2017 Apr; 77(7):1510-1541. PubMed ID: 28373404
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of immune-related adverse events associated with immune checkpoint blockade: using germline genetics to develop a personalized approach.
Khan Z; Hammer C; Guardino E; Chandler GS; Albert ML
Genome Med; 2019 Jun; 11(1):39. PubMed ID: 31221204
[TBL] [Abstract][Full Text] [Related]
13. The Value of Biomarkers in Optimizing the Use of Immuno-oncologic Therapy.
Ferreira CG; Nicolini A; Dalurzo L; Stefani S; Teich V; Leighl N
Curr Drug Targets; 2019; 20(1):81-86. PubMed ID: 30207218
[TBL] [Abstract][Full Text] [Related]
14. Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working Group.
Mandelker D; Donoghue M; Talukdar S; Bandlamudi C; Srinivasan P; Vivek M; Jezdic S; Hanson H; Snape K; Kulkarni A; Hawkes L; Douillard JY; Wallace SE; Rial-Sebbag E; Meric-Bersntam F; George A; Chubb D; Loveday C; Ladanyi M; Berger MF; Taylor BS; Turnbull C
Ann Oncol; 2019 Aug; 30(8):1221-1231. PubMed ID: 31050713
[TBL] [Abstract][Full Text] [Related]
15. Translating Immuno-oncology Biomarkers to Diagnostic Tests: A Regulatory Perspective.
Li Y; Veeraraghavan J; Philip R
Methods Mol Biol; 2020; 2055():701-716. PubMed ID: 31502175
[TBL] [Abstract][Full Text] [Related]
16. Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine.
Nebot-Bral L; Brandao D; Verlingue L; Rouleau E; Caron O; Despras E; El-Dakdouki Y; Champiat S; Aoufouchi S; Leary A; Marabelle A; Malka D; Chaput N; Kannouche PL
Eur J Cancer; 2017 Oct; 84():290-303. PubMed ID: 28846956
[TBL] [Abstract][Full Text] [Related]
17. Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA.
Schrader KA; Cheng DT; Joseph V; Prasad M; Walsh M; Zehir A; Ni A; Thomas T; Benayed R; Ashraf A; Lincoln A; Arcila M; Stadler Z; Solit D; Hyman DM; Zhang L; Klimstra D; Ladanyi M; Offit K; Berger M; Robson M
JAMA Oncol; 2016 Jan; 2(1):104-11. PubMed ID: 26556299
[TBL] [Abstract][Full Text] [Related]
18. The emerging significance of secondary germline testing in cancer genomics.
Mandelker D; Zhang L
J Pathol; 2018 Apr; 244(5):610-615. PubMed ID: 29293272
[TBL] [Abstract][Full Text] [Related]
19. Personalized Oncology Meets Immunology: The Path toward Precision Immunotherapy.
Mandal R; Chan TA
Cancer Discov; 2016 Jul; 6(7):703-13. PubMed ID: 27107038
[TBL] [Abstract][Full Text] [Related]
20. Next-Generation Sequencing in Oncology in the Era of Precision Medicine.
Blumenthal GM; Mansfield E; Pazdur R
JAMA Oncol; 2016 Jan; 2(1):13-4. PubMed ID: 26540172
[No Abstract] [Full Text] [Related]
[Next] [New Search]
